Data back a 4-fold higher dose of crenezumab in the CREAD 1 and CREAD 2 trials than used in phase II.
Geoff Kerchner, MD, PhD
Advertisement
Articles by Geoff Kerchner, MD, PhD
Higher doses of gantenerumab, a monoclonal antibody designed to bind to aggregated Aβ and remove beta plaques, will be investigated in phase III trials.
Advertisement
Latest Updated Articles
Geoff Kerchner, MD, PhD: Phase III Trials of Crenezumab in Treatment of Prodromal to Mild AlzheimerPublished: August 13th 2018 | Updated:
- Geoff Kerchner, MD, PhD: Gantenerumab as Disease-Modifying Treatment in Early Alzheimer Disease
Published: August 9th 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery
2
Women Physicians Day 2026: Sex-Specific Clinical Considerations in Women With Epilepsy
3
Biomarker Data Across Studies Support Disease-Targeted Effects of Valiltramiprosate
4
NeuroVoices: Benjamin Tolchin, MD, FAAN, on First-Ever AAN Guidelines for Functional Seizures
5